Tech Company Financing Transactions

Gemin X Pharmaceuticals Funding Round

Gemin X Pharmaceuticals secured a $50 million Series D financing round on 5/19/2005. Investors included H.I.G. Capital, Sanderling Ventures and Merlin BioMed Group.

Transaction Overview

Company Name
Gemin X Pharmaceuticals
Announced On
5/19/2005
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series D
Investors

H.I.G. Capital (Lead Investor) (Aaron Davidson)

Sanderling Ventures (Lead Investor) (Robert McNeil)

Merlin BioMed Group

Pinnacle Ventures

Proceeds Purpose
The funding will support Gemin X's continued clinical development of lead product candidate GX15-070, including an ongoing Phase 1/2 trial in patients with chronic lymphocytic leukemia (CLL) and a Phase 1 trial in patients with solid tumors. The funding will also be used to advance a second oncology compound in the company's pipeline, into the clinic.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
400 Chesterfield Parkway 100
Malvern, PA 19355
USA
Phone
(514) 281-8989
Website
www.geminx.com
Email Address
[email protected]
Overview
Gemin X Pharmaceuticals Inc. specializes in the discovery and development of novel small-molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells.
Profile
Gemin X Pharmaceuticals LinkedIn Company Profile
Social Media
Gemin X Pharmaceuticals Company Twitter Account
Company News
Gemin X Pharmaceuticals News
Facebook
Gemin X Pharmaceuticals on Facebook
YouTube
Gemin X Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Peter Dolan
  Peter Dolan LinkedIn Profile  Peter Dolan Twitter Account  Peter Dolan News  Peter Dolan on Facebook
Chief Financial Officer
Michael Dixon
  Michael Dixon LinkedIn Profile  Michael Dixon Twitter Account  Michael Dixon News  Michael Dixon on Facebook
Chief Medical Officer
Jean Viallet
  Jean Viallet LinkedIn Profile  Jean Viallet Twitter Account  Jean Viallet News  Jean Viallet on Facebook
Chief Scientific Officer
Gordon Shore
  Gordon Shore LinkedIn Profile  Gordon Shore Twitter Account  Gordon Shore News  Gordon Shore on Facebook
Vice President
Mark Berger
  Mark Berger LinkedIn Profile  Mark Berger Twitter Account  Mark Berger News  Mark Berger on Facebook
VP - Bus. Development
Art Fratamico
  Art Fratamico LinkedIn Profile  Art Fratamico Twitter Account  Art Fratamico News  Art Fratamico on Facebook
VP - Operations
Edwina Wyatt-Knowles
  Edwina Wyatt-Knowles LinkedIn Profile  Edwina Wyatt-Knowles Twitter Account  Edwina Wyatt-Knowles News  Edwina Wyatt-Knowles on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/18/2005: Wright Medical venture capital transaction
Next: 5/20/2005: Endius venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.